Trial · NCT07910968
SWitching to Appropriate Prescription in Cardiovascular-Kidney-Metabolic Syndrome
NCT07910968, Not applicable, Not yet recruiting, Kaiser Permanente
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. SWitching to Appropriate Prescription in Cardiovascular-Kidney-Metabolic Syndrome. Trials, record NCT07910968. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07910968
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- SWitching to Appropriate Prescription in Cardiovascular-Kidney-Metabolic Syndrome
- NCT number
- NCT07910968
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 1,200 participants, estimated
- Lead sponsor
- Kaiser Permanente
- Conditions
- Cardiovascular-kidney-metabolic Syndrome, Diabete Type 2, Chronic Kidney Disease, Heart Failure
- Interventions
- Real-Time EHR Prompts and Audit-and-Feedback Reports
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of Therapeutic Optimization Opportunities Achieved | 9 months | Proportion of eligible therapeutic optimization opportunities achieved, defined as the number of achieved opportunities divided by the total number of eligible opportunities. Each therapeutic swap includes two opportunities: discontinuation of a potentially inappropriate medication and initiation of the corresponding evidence-based medication. Individual patients may contribute multiple opportunities. |
| Secondary | Proportion of Implementation Optimization Opportunities Achieved | 9 months | Proportion of eligible implementation opportunities achieved, defined as the number of achieved opportunities divided by the total number of eligible implementation opportunities. Implementation refers to initiation of the corresponding evidence-based medication. Individual patients may contribute multiple opportunities. This will be assessed overall and by SWAP type. |
| Secondary | Proportion of De-implementation Optimization Opportunities Achieved | 9 months | Proportion of eligible de-implementation opportunities achieved, defined as the number of achieved opportunities divided by the total number of eligible de-implementation opportunities. De-implementation refers to discontinuation of a potentially inappropriate or harmful medication. Individual patients may contribute multiple opportunities. This will be assessed overall and by SWAP type. |
| Secondary | Proportion of Patients With Polypharmacy | 9 & 18 months | Proportion of patients with polypharmacy, defined as concurrent use of five or more medications at the 9-month and 18-month assessments. |
| Secondary | Proportion of Patients With Hyper-polypharmacy | 9 & 18 months | Proportion of patients with hyper-polypharmacy, defined as concurrent use of ten or more medications at the 9-month and 18-month assessments. |
| Other | Number of Participants With All-Cause Hospitalization | 9 & 18 months | Number of participants experiencing at least one hospitalization for any cause during the follow-up period, identified using electronic health record data. |
| Other | Number of Participants with All-Cause Mortality | 9 & 18 months | Number of participants who died from any cause during the follow-up period, ascertained using routinely collected health system data. |
| Other | Proportion of Eligible Patients Included in SWAP-CKM | 9 & 18 months | Proportion of patients included in SWAP-CKM among all patients meeting study eligibility criteria within Kaiser Permanente Northern California. Reach will also be characterized across demographic and clinical subgroups. |
| Other | Proportion of Eligible Therapeutic Swaps Adopted by Clinicians | 9 & 18 months | Proportion of eligible therapeutic swaps adopted by clinicians, defined as the number of recommended swaps implemented divided by the total number of eligible swaps. Adoption will be evaluated across patient characteristics, clinician types, and therapeutic swap categories. |
| Other | Number of SWAP-CKM Electronic Advisory Firings | 9 & 18 months | Total number of SWAP-CKM electronic OurPractice Advisory (OPA) firings recorded during the study period, summarized over time to assess patterns of intervention maintenance and health system learning. |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07910968
GET https://conductscience.org/api/trials/v1/NCT07910968/registered